Research programme: antibody and small molecule therapeutics - Applied Immunotherapeutics/Feinstein Institute for Medical Research

Drug Profile

Research programme: antibody and small molecule therapeutics - Applied Immunotherapeutics/Feinstein Institute for Medical Research

Latest Information Update: 02 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Karolinska Institute; The Feinstein Institute for Medical Research
  • Class Anti-inflammatories; Antianaemics; Antibodies; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action HMGB1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Anaemia; Autoimmune disorders; Diabetes mellitus; Inflammation; Inflammatory bowel diseases; Rheumatoid arthritis

Most Recent Events

  • 12 Jul 2017 Feinstein Institute and Applied Immunotherapeutics agree to co-develop antibodies and small molecule therapeutics for inflammatory and autoimmune diseases
  • 12 Jul 2017 Early research in Anaemia in Sweden, USA
  • 12 Jul 2017 Early research in Autoimmune disorders in Sweden, USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top